A Study of TAS-120 in Patients With Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor
Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with
the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic
breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who
have previously received conventional therapies to treat their breast cancer, or who are not
able to tolerate certain cancer therapies. This study will also evaluate the safety of taking
futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.